Trials / Recruiting
RecruitingNCT06079671
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
Detailed description
Women with locally advanced cervical cancer will be randomized in a 1:1 ratio to receive treatment with Volrustomig or Placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Volrustomig | IV Infusion |
| OTHER | Placebo | IV Infusion |
Timeline
- Start date
- 2023-09-22
- Primary completion
- 2027-11-26
- Completion
- 2030-09-30
- First posted
- 2023-10-12
- Last updated
- 2026-04-02
Locations
201 sites across 19 countries: United States, Brazil, Canada, China, Denmark, Germany, India, Italy, Japan, Mexico, Norway, Peru, Poland, Puerto Rico, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06079671. Inclusion in this directory is not an endorsement.